Xu, Kun
Novartis (United States)
2 papers on CoChatORCID 0000-0003-2127-5516
Most cited papers
- Verified
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 150
- Verified
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors
Brana, I., Shapiro, G., Johnson, M. L., Yu, H. A., Robbrecht, D., Tan, D. S.-W., Siu, L. L., Minami, H., Steeghs, N., Hengelage, T., et al. (2021) · Journal of Clinical Oncology
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 79
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free